NZSE:AFTPharmaceuticals
AFT Pharmaceuticals (NZSE:AFT) EPS Rebound Tests Premium P/E And Non Cash Earnings Concerns
AFT Pharmaceuticals (NZSE:AFT) has opened FY 2026 with first half revenue of NZ$114.9 million and basic EPS of NZ$0.03, putting fresh numbers on the table for investors following its growth story. The company has seen revenue move from NZ$86.7 million and basic EPS of a NZ$0.02 loss in the first half of FY 2025 to NZ$121.3 million and basic EPS of NZ$0.14 in the second half of FY 2025, with trailing 12 month EPS most recently sitting at NZ$0.14 on revenue of NZ$254.7 million and net income of...